BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 14730466)

  • 1. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
    Tutrone WD; Saini R; Weinberg JM
    IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R; Tutrone WD; Weinberg JM
    Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ; Bello-Quintero CE
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH; Prinz J; Gottlieb AB
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG; Gupta AK; Cherman AM; Inniss KA
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
    Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP; Lewis VJ; Finlay AY
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE; Nunley K; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating biologic therapies into a dermatology practice: practical and economic considerations.
    Craze M; Young M
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S139-42. PubMed ID: 12894138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining traditional agents and biologics for the treatment of psoriasis.
    Cather JC; Menter A
    Semin Cutan Med Surg; 2005 Mar; 24(1):37-45. PubMed ID: 15900797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of biologic agents in medicine and dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2005 Mar; 24(1):2-9. PubMed ID: 15900793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.